Inflammatory conditions elicited by extrinsic environmental factors promote malignant cell transformation, tumor growth, and metastasis. Although most attention has been focused on innate immune mechanisms of inflammatory carcinogenesis, more recently the role of T cells in cancer promotion has been examined. Although IFN-dependent Th1 responses that promote Stat1 signaling inhibit tumor growth, the role of T helper type 17 responses, and interleukin-17 (IL-17) in particular, has been controversial. Indeed, IL-17 has been reported to either enhance or inhibit the growth of transplantable tumors, depending on the system. Little is known about the role of IL-17 in de novo carcinogenesis. Using IL-17 knockout mice, we examined the role of IL-17 in the classic DMBA/TPA-induced skin carcinogenesis model. Disruption of IL-17 dramatically reduced tumorigenesis in this model in a manner correlated with diminished Stat3 activation in the tumor microenvironment. IL-17 loss reduced Stat3-associated proliferative and antiapoptotic gene expression along with epidermal cell proliferation and hyperplasia. In addition, IL-17 loss was associated with reduced expression of Stat3-regulated chemokines that attract myeloid cells and a decreased infiltration of myeloid cells into the local tumor microenvironment. Together, our findings point to a critical role of the IL-17-Stat3 pathway in supporting cancer-associated inflammation in the tumor microenvironment. Therapeutic approaches that target this pathway may therefore be effective to inhibit carcinogenesis.
Introduction
Epidemiologic studies identified chronic inflammation as a major risk factor for various types of cancer (1) . As a core transcriptional mediator of inflammation, NF-kB activation is a central component of procarcinogenic innate immune responses (2) . In a number of systems, Stat3 activation in both epithelial and myeloid cells is a critical downstream mediator of tumorigenesis (3) (4) (5) . Stat3 activation in epithelial cells drives the transcription of cyclin-dependent kinases, antiapoptotic genes, and proangiogenesis genes, all of which are important for tumor growth (5) . Stat3 activation in myeloid cells has been shown to inhibit transcription of the antitumor cytokine interleukin-12 (IL-12) while promoting expression of the procarcinogenic IL-12 family cytokine IL-23 (6) . More recently, attention has turned to the role of adaptive immunity, particularly T cell-mediated responses, in tumorigenesis. T-cell immunity can promote or inhibit cancer development and growth (7) (8) (9) (10) (11) and it is therefore critical to determine how specific T-cell lineages selectively affect cancer growth. T helper type 1 (Th1) responses promoted by IL-12 seem to mediate antitumor responses via production of IFN-g and enhancement of antitumor CTLs (12) . Stat1 signaling is important in both the induction and effector phases of Th1-type immunity (13) . The nature of T-cell responses that promote carcinogenesis and cancer growth is less clear. A number of colon carcinogenesis models have suggested a positive association between the major Th17 cytokine IL-17A (commonly termed IL-17) and cancer development (14) . This makes sense, as Stat3 signaling is not only procarcinogenic but also central to Th17 differentiation and function (15) . In addition, the Stat3-induced procarcinogenic cytokine IL-23 maintains and mediates expansion of Th17 cells (16) . However, the role of IL-17 in growth of established tumors is unclear. Although several reports suggest that certain transplanted tumors grow more slowly in mice lacking either IL-17 or IL-17 receptor (7, 9) , other groups have reported increased growth of transplanted tumors in the absence of IL-17, suggesting that the role of IL-17 in cancer is context dependent (17, 18) . Moreover, clinically, the presence of Th17 cells in tumors has been associated with both favorable and unfavorable prognoses (19) (20) (21) . These conflicting observations warrant further investigations into the role of IL-17 in cancer.
To further assess the role of IL-17 in the carcinogenesis process, we have explored a classic model of inflammationAuthors' Affiliations:
1 Department of Cancer Immunotherapeutics and Tumor Immunology, induced skin cancer, using 7,12-dimenthylbenz[a]anthracene (DMBA) and 12-o-tetradecanoylphorbol-13-acetate (TPA). This model has been widely used to study how an extrinsic chemically induced inflammation initiates epithelial transformation and promotes subsequent papilloma development (22, 23) . In this 2-stage carcinogenesis model, DMBA induces mutations in dermal epithelium at the earliest stage whereas TPA administration elicits an inflammatory response that mediates further transformation, resulting in papilloma development.
We show that IL-17 is an important tumor-promoting element in DMBA/TPA skin carcinogenesis. IL-17 induces Stat3 activation, epithelial hyperproliferation, and CD11b þ Gr-1 þ myeloid cell infiltration at the site of tumor initiation. Our findings support the notion that Th17 responses can enhance carcinogenesis.
Materials and Methods

Animals and animal care
Wild-type (WT) mice were purchased from the National Cancer Institute unless indicated specifically. IFN-g À/À C57BL/6 mice were purchased from The Jackson Laboratory. The generation of C57BL/6 IL-17 À/À mice has been previously reported (24) , and the mice were provided by Y. Iwakura (University of Tokyo). Mouse care and experimental procedures were performed under pathogen-free conditions in accordance with established institutional guidance and approved protocols from the Research Animal Care Committee of the City of Hope Medical Center (Duarte, CA).
DMBA/TPA-induced epithelial carcinogenesis procedure The 2-stage skin carcinogenesis was conducted on the basis of peer reports (23) . Briefly, the dorsal skin of mice was shaved and painted with DMBA (Sigma) in 200 mL of acetone at 100 mg per mouse once and then treated with TPA in 200 mL of acetone at 30 mg per mouse twice a week. Mice were evaluated weekly for papilloma development. Only tumors that had attained a size of 1 mm or greater and were present for a week or more were counted.
Isolation of mononuclear cells from skin
Mononuclear cell isolation from skin was performed as previously described (25) . Briefly, dorsal skin (3 Â 3 cm 2 ) was cut into small pieces and shaken in RPMI containing 5% fetal bovine serum, 10 mmol/L of HEPES (Irvine Scientific), 0.01% DNase (Sigma-Aldrich), 0.27% collagenase type I (SigmaAldrich), and 1,000 U/mL of hyaluronidase (Sigma-Aldrich) at 37 C for 1 hour. Skin tissue and suspension were then intensively washed with PBS containing 2 mmol/L of EDTA and filtered with a 70-mm cell strainer before enrichment with Lympholyte M (Accurate Chemical & Scientific).
Monoclonal antibodies and flow cytometric analysis
Antibodies to mouse CD4, CD8, TCRb, CD11b, Gr-1, IL-17, and IFN-g were all purchased from eBioscience. For intracellular staining, cells were stimulated with plate-bound CD3/ CD28 for 5 hours, and Brefeldin A (10 mg/mL) was added in the last 2 hours. Cells were then harvested and stained for cytokines. Dead cells were excluded by Fixable Aqua Dead Cell Stain kit (Invitrogen).
Immunofluorescence staining
Paraffin-embedded specimens were deparaffinized, hydrated, and autoclaved in antigen unmasking solution (Vector) before being stained with antibodies specific to Ki67 (Abcam). Specimens were then detected with secondary antibodies conjugated to Alexa Fluor 488 (Invitrogen). After staining with Hoechst 33342 (Invitrogen) to visualize cell nuclei, slides were mounted and analyzed by fluorescence microscopy.
Real-time quantitative PCR
Total RNA from skin sample was extracted by RNeasy Fibrous Tissue kit (Qiagen) and cDNA was synthesized using iScript cDNA Synthesis kit (Bio-Rad). Mouse IL-17, IL-6, Bcl-X L , survivin, cyclin D1, tumor necrosis factor-a (TNF-a), IL-1b, CXCL2, and cyclooxygenase-2 (Cox-2) primers were purchased from SABiosciences. Sequence for CXCL1 primers is as follows:
0 . Sequence for S100A8 primer is as follows: sense, 5 0 -CCAATTCTCTGAACAAGTTTTCG-3 0 ; antisense, 5 0 -TCACCATGCCCTCTACAAGA-3 0 . Sequence for S100A9 primer is as follows: sense, 5
0 -GTCCAGGTCCTCCAT-GATGT-3 0 ; antisense, 5 0 -TCAGACAAATGGTGGAAGCA-3 0 .
Statistical analysis
Unpaired t test was used to calculate the 2-tailed P value. Data were analyzed using Prism software (GraphPad Software, Inc.). For real-time reverse transcription (RT)-PCR, data before normalization were used for t-test analysis.
Results
Elevated IL-17 expression and Stat3 activation in DMBA/TPA-administrated mice
To study the role of IL-17 in skin carcinogenesis, we first examined the expression of IL-17 in skin after DMBA/TPA administration. We found that the expression of IL-17 was induced approximately 4-fold after 3 hours of the first TPA administration (Fig. 1A) . Consistent with our previous observation that IL-17 can induce IL-6 expression (9), we observed similar kinetics for IL-6 expression after the TPA administration (Fig. 1A) . After the repeated biweekly application of TPA for 20 weeks, the expression of IL-17 and IL-6 was further increased and constitutively maintained at a high level in skin of TPA-treated mice (Fig. 1A) . These results indicate that DMBA/TPA administration can elicit a strong IL-17 response, with associated inflammation in the local epidermal environment.
We next investigated whether TPA-induced IL-17 and IL-6 production would mediate Stat3 activation. We observed that Stat3 phosphorylation was also markedly increased in skin 3 hours post-TPA administration but reduced 24 hours post-TPA administration (Fig. 1B) . Stat3 activation was maintained at a high level after long-term TPA treatment (Fig. 1B) . Taken together, these results indicate that DMBA/TPA administration elicits a strong induction of IL-17 in epidermal local environment, which is associated with constitutively activated Stat3 signaling.
IL-17
À/À mice are resistant to the DMBA/TPA-induced epithelial carcinogenesis We next assessed the role of IL-17 in this skin carcinogenesis model using genetic knockout. Sex-, age-, and matched WT and IL-17 À/À mice were administrated with DMBA/TPA.
We found that the IL-17 À/À mice were strongly resistant to DMBA/TPA-induced carcinogenesis as compared to WT controls. While about 80% of WT mice developed papillomas by 13 weeks post-DMBA/TPA administration, only 10% of the IL-17 À/À mice developed any papillomas ( Fig 
IL-17 ablation leads to reduced Stat3 activation in the tumor microenvironment
To determine the mechanism(s) by which IL-17 promotes papilloma development, we next performed intracellular cytokine staining to measure IL-17 production in the inflammatory skin. There were approximately 4% of CD4 þ T cells from the skin of DMBA/TPA-treated WT mice producing IL-17, whereas IL-17 secreting cells were not detectable in the IL-17 À/À mice (Fig. 3A, left) . The lack of IL-17 expression in IL-17 À/À mice was confirmed by real-time PCR (Fig. 3A, right) .
We did not detect any IL-17 production in non-T cells by intracellular staining (data not shown). These results indicate that DMBA/TPA administration stimulates classic Th17 cell production of IL-17, which exerts an important role in promoting carcinogenesis-associated inflammation. We previously reported that IL-17 is essential for the activation of Stat3 in an IL-6-dependent manner in transplantable tumor models (9) . We next tested whether loss of IL-17 also led to reduced IL-6 expression and Stat3 activity in inflammation-driven skin carcinogenesis. IL-6 expression in the skin samples from TPA-administrated WT versus IL-17
mice was compared by real-time PCR. We found that IL-6 expression was reduced in the skin samples prepared from IL-17 À/À mice as compared with those of WT mice (Fig. 3B ).
The reduction of IL-6 in IL-17 À/À mice was associated with downmodulated Stat3 activation in skin samples, as detected by phosphorylated Stat3 (p-Stat3; Fig. 3C ). p-Stat3 activity was also assessed by immunofluorescence staining. Stat3 was activated in epidermal layer, outer root sheath of hair follicle, and epidermal-and dermal-infiltrating cells in WT skin samples, whereas its activation was reduced in skin from IL-17 (Fig. 4A) . We also compared expression of several of Stat3-regulated proliferative and antiapoptotic genes in DMBA/TPA-treated skin samples from WT and IL-17
mice. We found that Stat3 signature oncogenic genes, such as cyclin D1, bcl-x L , and survivin, were markedly reduced in IL-17 À/À mice as compared with WT control (Fig. 4B and C) .
Taken together, these results suggest that DMBA/TPAinduced IL-17 plays a critical role in promoting epithelial cell hyperproliferation through the induction of Stat3 and its regulated oncogenic gene expression. a a a a a a a a a a a a a a  Ca a a a a a a a a a 
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Although CD8 (27, 28) . We next compared expression of IL-6/Stat3-regulated inflammatory mediators in skin from DMBA/TPA-treated WT and IL-17 À/À mice.
We found that the expression of IL-1b, CXCL1, CXCL2, S100A8, S100A9, Cox-2, and TNF-a was significantly reduced in skin samples from IL-17 À/À mice as compared with WT controls (Fig. 5C ). All of these cytokines and chemokines have been reported to promote myeloid-derived suppressor cell generation and recruitment into the inflammatory environment (27, (29) (30) (31) . In contrast, we did not observe reduced expression of T cell-attracting chemokines, such as CXCL9-11, but reduced expression of matrix metalloproteinase 9 (MMP9), IL-17F, and IL-21 ( Supplementary Fig. S4A-C) .
COX-2
Yield (33) . Although overactivation of various tyrosine kinases induces persistent Stat3 activation in transformed cells, Stat3 activation in the tumor microenvironment is mediated by many extrinsic mediators, including cytokines (e.g., IL-6, IL-10, and IL-23) and growth factors (vascular endothelial growth factor and fibroblast growth factor 2) whose receptors are known to signal through Stat3 (6, 34) . We previously reported that in the tumor progression stage, IL-17 is a potent activator of Stat3 signaling through stimulating IL-6 production (9). In the current study, we showed that IL-17 triggered by the extrinsically administered chemical TPA played a critical role in elevating Stat3 signaling and its associated gene transcription in the tumor initiation stage, which subsequently promotes malignant cell proliferation and formation of papillomas. This observation is in agreement with a recent report showing that a human colonic commensal [enterotoxogenic Bacteroides fragilis (ETBF)] promotes colon tumorigenesis in a Th17-Stat3-dependent manner (14) . These studies emphasize an important role of IL-17 in activating Stat3 in tumor-associated inflammatory conditions. However, our results do not address the role of IL-17 in the initiation stage of papilloma development. Using IL-17 neutralizing antibody before DMBA treatment may provide important information on whether IL-17 is critical for papilloma development at early stages.
Previous studies have demonstrated a critical role of TNFa/NF-kB axis in the DMBA/TPA skin carcinogenesis model (35) . It has been shown that TNF-a contributed to tumor progression by increasing myeloid cell recruitment in an IL-17-dependent way (36) . In our study, we observed reduction of TNF-a in IL-17 À/À mice. At this point, it remains to be clarified whether Stat3 signaling inhibits TNF-a indirectly or directly. Several independent studies have shown that NF-kBinduced tumorigenesis is Stat3 dependent (37) . Although consistent with several recent publications on the role of IL-17 in promoting growth of transplanted tumor growth (7, 9) and ETBF-induced colon tumorigenesis in Min mice (14) , these findings contradict other reports suggesting that IL-17 can provide an antitumor effect against certain transplanted tumors (17, 18) . In addition, a recent report demonstrated that lung metastases from polyoma middle T-driven breast cancer involved a Th2-dependent mechanism (38) . It is therefore possible that cytokine requirements for growth versus inhibition of established tumors or metastases may be diverse depending on tumor type and expression of cytokine receptors by tumor cells themselves. These requirements are likely quite different from de novo carcinogenesis that seems to be enhanced by IL-17 and Stat3 signaling. Further analysis of additional examples of transplanted tumors, natural metastases, and de novo carcinogenesis will be necessary to define whether there are common or distinct immunologic responses for these processes.
The IL-17-Stat3 pathway can promote epithelial carcinogenesis at multiple levels. First, as an oncogenic transcription factor, Stat3 activation in epithelial cells is associated with cell proliferation and antiapoptosis. We observed that Stat3 is constitutively activated in DMBA/TPA-treated skin, which is associated with elevated expression of Stat3-regulated proliferation and antiapoptosis genes. Downmodulated Stat3 activation in IL-17 À/À mice resulted in reduced epithelial cell hyperproliferation and gland hyperplasia and downregulated oncogenic gene expression. Second, Stat3 activation can result in dysregulated immune surveillance against tumors. Tumorinfiltrating myeloid cells are reported to be immunosuppressive and can facilitate malignant cells escaping from the immune surveillance. The IL-17-Stat3 pathway augments the recruitment of myeloid cells but not of CD8 þ T cells into the local skin environment. Stat3-regulated inflammatory mediator expression, including Cox-2, CXCL1, CXCL2, S100A8, S100A9, and IL-1b, has been reported to be critical for the generation of myeloid suppressive cells and granulocyte cells into the inflammatory environment (27, (29) (30) (31) . Finally, IL-17-Stat3 signaling can upregulate MMP9 expression to facilitate the tumor angiogenesis. In agreement with this notion, we observed that lack of IL-17 is associated with reduced MMP9 expression ( Supplementary Fig. S4B ). In summary, our study has emphasized an important role of IL-17-Stat3 pathway in promoting epithelial carcinogenesis. Therapies that target IL-17 and Stat3 may be developed as potential therapeutic approaches to inhibit carcinogenesis.
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